MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2024 Financial Results
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) has announced it will release its full year and fourth quarter 2024 financial results on Monday, March 31st, 2025, before markets open. The pharmaceutical company, which specializes in precision-based cannabinoids, will make available an updated company presentation including select highlights from the period ended December 31st, 2024 on their website following the earnings release. The company has noted that this presentation will replace a quarterly earnings call with management.
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) ha annunciato che rilascerà i suoi risultati finanziari per l'intero anno e il quarto trimestre del 2024 lunedì 31 marzo 2025, prima dell'apertura dei mercati. L'azienda farmaceutica, specializzata in cannabinoidi basati sulla precisione, renderà disponibile una presentazione aziendale aggiornata che includerà i principali risultati del periodo conclusosi il 31 dicembre 2024 sul proprio sito web dopo il rilascio dei risultati. L'azienda ha fatto sapere che questa presentazione sostituirà una chiamata trimestrale sugli utili con la direzione.
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) ha anunciado que publicará sus resultados financieros del año completo y del cuarto trimestre de 2024 el lunes 31 de marzo de 2025, antes de la apertura de los mercados. La compañía farmacéutica, que se especializa en cannabinoides basados en la precisión, pondrá a disposición una presentación actualizada de la empresa que incluirá los aspectos más destacados del período que finalizó el 31 de diciembre de 2024 en su sitio web después de la publicación de los resultados. La empresa ha señalado que esta presentación reemplazará una llamada trimestral sobre ganancias con la dirección.
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF)는 2025년 3월 31일 월요일, 시장 개장 전에 2024년 전체 연도 및 4분기 재무 결과를 발표할 것이라고 발표했습니다. 정밀 기반의 카나비노이드에 전문화된 제약 회사는 2024년 12월 31일로 종료된 기간의 주요 하이라이트를 포함한 업데이트된 회사 프레젠테이션을 수익 발표 후 웹사이트에 게시할 예정입니다. 회사는 이 프레젠테이션이 경영진과의 분기별 수익 통화를 대체할 것이라고 밝혔습니다.
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) a annoncé qu'elle publiera ses résultats financiers de l'année complète et du quatrième trimestre 2024 le lundi 31 mars 2025, avant l'ouverture des marchés. L'entreprise pharmaceutique, spécialisée dans les cannabinoïdes basés sur la précision, mettra à disposition une présentation mise à jour de l'entreprise qui inclura les principaux points saillants de la période se terminant le 31 décembre 2024 sur son site web après la publication des résultats. L'entreprise a noté que cette présentation remplacera un appel trimestriel sur les bénéfices avec la direction.
MediPharm Labs (TSX: LABS) (OTCQB: MEDIF) hat angekündigt, dass am Montag, den 31. März 2025, vor Markteröffnung die Jahres- und vierteljährlichen Finanzzahlen für 2024 veröffentlicht werden. Das Pharmaunternehmen, das sich auf präzisionsbasierte Cannabinoide spezialisiert hat, wird nach der Veröffentlichung der Ergebnisse eine aktualisierte Unternehmenspräsentation zur Verfügung stellen, die ausgewählte Höhepunkte des zum 31. Dezember 2024 endenden Zeitraums enthält. Das Unternehmen hat darauf hingewiesen, dass diese Präsentation einen vierteljährlichen Gewinnanruf mit dem Management ersetzen wird.
- None.
- None.
An updated company presentation including select highlights from the period ended December 31st, 2024 will be available on MediPharm's website following the earnings release, this in lieu of a quarterly earnings call hosted by management.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Website: www.medipharmlabs.com
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding the release of MediPharm's financial results and the future of MediPharm's foreign drug manufacturing site registration. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-full-year-and-fourth-quarter-2024-financial-results-302411608.html
SOURCE MediPharm Labs Corp.
FAQ
When will MediPharm Labs (MEDIF) release its Q4 2024 earnings?
Will MediPharm Labs (MEDIF) hold an earnings call for Q4 2024 results?
What period will MediPharm Labs' (MEDIF) upcoming financial report cover?
Where can investors find MediPharm Labs' (MEDIF) Q4 2024 earnings presentation?
